Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial

JAMA

Volumn 284, Issue 2, 2000, Pages 183-189

  Davey, Richard T ^a   Murphy, Robert L ^b   Graziano, Frank M ^b   Boswell, Stephen L ^b   Pavia, Andrew T ^b   Cancio, Margarita ^b   Nadler, Jeffrey P ^b   Chaitt, Doreen G ^b   Dewar, Robin L ^b   Sahner, David K ^b   Duliege, Anne Marie ^b   Capra, William B ^b   Leong, Wai Ping ^b   Giedlin, Martin A ^b   Lane, H Clifford ^b   Kahn, James O ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; IBUPROFEN; INTERLEUKIN 2; NARCOTIC AGENT; PARACETAMOL;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDRATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0004781509     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.284.2.183     Document Type: Article

References (26)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al, for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
3. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin 2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr. 1991;4:11-23.
4. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin 2 in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med. 1995;332:567-575.
5. McMahon DK, Armstrong JA, Huang X-L, et al. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine. AIDS. 1994;8:59-66.
6. 3: results of a randomized, controlled trial. N Engl J Med. 1996;335:1350-1356.
7. Davey RT Jr, Chaitt DG, Piscitelli SC, et al. Subcutaneous administration of interleukin-2 in HIV-1-infected persons. J Infect Dis. 1997;175:781-789.
8. De Paoli P, Zanussi S, Simonelli C, et al. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J Clin Invest. 1997;100:2737-2743.
9. Emery S, Capra W, Vig P, et al. IL-2 therapy for HIV disease: a meta-analysis of three randomized, controlled trials. From: Fifth Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 608.
10. Carr A, Emery S, Lloyd A, et al, for the Australian IL-2 Study Group. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. J Infect Dis. 1998;178:992-999.
11. Davey RT Jr, Chaitt DC, Albert JM, et al. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis. 1999;179:849-858.
12. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41(RR-17):4-19.
13. + T-cell determinations in persons with human immunodeficiency virus (HIV) infections. MMWR Morb Mortal Wkly Rep. 1994;42(RR-3):1-21.
14. Urdea MS, Wilber JC, Yeghiazarian T, et al. Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. AIDS. 1993;7(suppl 2):S11-S14.
15. Dewar R, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis. 1994;170:1172-1179.
16. Pavur R, Nath R. Parametric versus rank transform procedures in the two-way factorial experiment: a comparative study. J Stat Computation Simulation. 1986;23:231-240.
17. Van Lunzen J, Tenner-Racs K, Racz P, Hufert FT, Lauer J, Stellbrink HJ. Effect of HAART +/-IL-2 on viral kinetics and T-cell reconstitution in lymphoid tissues of asymptomatic HIV-1 infected patients. Int Conf AIDS. 1998;12:787-788.
18. Hengge UR, Goos M, Esser S, et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS. 1998;12:F225-F234.
19. Levy Y, Capitant C, Houhou S, et al, for the ANRS 048 Study Group. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. Lancet. 1999; 353:1923-1929.
20. Zanussi S, Simonelli C, Bortolin MT, et al. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2. Clin Exp Immunol. 1999;116:486-492.
21. Arno A, Ruiz L, Juan M, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load. J Infect Dis. 1999;180:56-60.
22. Jacobson EL, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV-positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci U S A. 1996;93:10405-10410.
23. Clark AG, Holodmiy M, Schwartz DH, Katzenstein DA, Merigan TC. Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. J Acquit Immune Defic Syndr. 1992;5:52-59.
24. Simonelli C, Zanussi S, Sandri S, et al. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:20-27.
25. Izopet J, Salama G, Pasquier C, et al. Ultra sensitive detection of plasma HIV-1 RNA for predicting the durability of 3-drug antiretroviral therapy. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 326.
26. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9-F14.